JP6948080B2 - 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 - Google Patents
手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 Download PDFInfo
- Publication number
- JP6948080B2 JP6948080B2 JP2019547371A JP2019547371A JP6948080B2 JP 6948080 B2 JP6948080 B2 JP 6948080B2 JP 2019547371 A JP2019547371 A JP 2019547371A JP 2019547371 A JP2019547371 A JP 2019547371A JP 6948080 B2 JP6948080 B2 JP 6948080B2
- Authority
- JP
- Japan
- Prior art keywords
- hepatocellular carcinoma
- patients
- invasive
- tumor
- microvascularly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465170P | 2017-03-01 | 2017-03-01 | |
| US62/465,170 | 2017-03-01 | ||
| US201762504552P | 2017-05-11 | 2017-05-11 | |
| US62/504,552 | 2017-05-11 | ||
| US201762551770P | 2017-08-29 | 2017-08-29 | |
| US62/551,770 | 2017-08-29 | ||
| PCT/CN2018/077105 WO2018157762A1 (en) | 2017-03-01 | 2018-02-24 | Use of sulfated oligosaccharides in the manufacture of a medicament for treating patients with hepatocellular carcinoma after surgical resection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509035A JP2020509035A (ja) | 2020-03-26 |
| JP2020509035A5 JP2020509035A5 (enExample) | 2020-07-09 |
| JP6948080B2 true JP6948080B2 (ja) | 2021-10-13 |
Family
ID=63357147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547371A Active JP6948080B2 (ja) | 2017-03-01 | 2018-02-24 | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10842804B2 (enExample) |
| JP (1) | JP6948080B2 (enExample) |
| KR (1) | KR102265159B1 (enExample) |
| CN (1) | CN110381953A (enExample) |
| TW (1) | TWI693071B (enExample) |
| WO (1) | WO2018157762A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113160911A (zh) * | 2021-02-26 | 2021-07-23 | 杭州臻合健康科技有限公司 | 一种用于术前肝功能耐受性分析的评估系统 |
| CN117476246B (zh) * | 2023-12-25 | 2024-04-19 | 福建大数据一级开发有限公司 | 基于多类型复发事件的患者生存分析方法、介质及装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7875592B2 (en) * | 2004-03-04 | 2011-01-25 | Progen Pharmaceuticals Limited | Sulfated oligosaccharide derivatives |
| CN103547270A (zh) | 2011-06-09 | 2014-01-29 | 基亚生物科技股份有限公司 | 用于抑制肝癌复发、恶化或转移之医药组成物 |
-
2018
- 2018-02-08 US US15/892,343 patent/US10842804B2/en active Active
- 2018-02-24 JP JP2019547371A patent/JP6948080B2/ja active Active
- 2018-02-24 CN CN201880014397.6A patent/CN110381953A/zh active Pending
- 2018-02-24 KR KR1020197028654A patent/KR102265159B1/ko active Active
- 2018-02-24 WO PCT/CN2018/077105 patent/WO2018157762A1/en not_active Ceased
- 2018-02-26 TW TW107106359A patent/TWI693071B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190120339A (ko) | 2019-10-23 |
| TWI693071B (zh) | 2020-05-11 |
| JP2020509035A (ja) | 2020-03-26 |
| US10842804B2 (en) | 2020-11-24 |
| US20180250317A1 (en) | 2018-09-06 |
| WO2018157762A1 (en) | 2018-09-07 |
| KR102265159B1 (ko) | 2021-06-17 |
| TW201840324A (zh) | 2018-11-16 |
| CN110381953A (zh) | 2019-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Friedman et al. | Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer | |
| US20240360235A1 (en) | Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment | |
| Willemze et al. | Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| EP3570840B1 (en) | Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer | |
| Qu et al. | Efficacy and safety of TACE combined with lenvatinib plus PD-1 inhibitors compared with TACE alone for unresectable hepatocellular carcinoma patients: a prospective cohort study | |
| TW202043274A (zh) | 用於晚期實性瘤癌症之治療性ｒｎａ及抗ｐｄ１抗體 | |
| JP2019503387A (ja) | 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法 | |
| Liang et al. | Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial | |
| Tu et al. | Case report: a case of sintilimab-induced cystitis/ureteritis and review of sintilimab-related adverse events | |
| Akamatsu et al. | Pembrolizumab plus amrubicin in patients with relapsed SCLC: multi-institutional, single-arm phase 2 study | |
| JP6948080B2 (ja) | 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 | |
| WO2022089377A1 (en) | Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer | |
| Guo et al. | Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma | |
| Sawa et al. | A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia | |
| KR20240162547A (ko) | 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법 | |
| Subudhi | A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC) | |
| Bozorgmehr et al. | Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415) | |
| TW202529802A (zh) | 胃癌和／或胃食管結合部癌的治療 | |
| Zhang et al. | Boosting the abscopal effect with chemoradiotherapy/immunotherapy combination in metastatic cervical cancer: a case report | |
| Khan et al. | Failure of the PD-1 blocking agent pembrolizumab to benefit a patient with renal squamous cell cancer | |
| Zeng et al. | Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study | |
| Gang et al. | Whether AI+ CDK4/6i+ HP is suitable treatment for three positive metastatic breast cancer patient with renal insufficiency caused by type 2 diabetes | |
| Zhang et al. | Gastrointestinal (Non-colorectal) Cancer | |
| DEVELOPM | Drug DeveloPment | |
| Leemans | Short title NeoNivo EudraCT number 2018-002643-28 Version 9 Date 11-12-2019 Principal investigators C. Willemien Menke-van der Houven van Oordt, MD PhD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200521 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200521 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200521 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200610 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210719 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210907 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210910 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6948080 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |